1. IGF-I and epidermal growth factor levels in follicular fluid of women undergoing controlled ovarian hyperstimulation using the multidose GnRH-antagonist protocol or the long GnRH-agonist protocol

   • B. Asimakopoulos
   • B. Schöpper
   • N. Nikolettos

   Rapid Communication 11 March 2014 Pages: RC5 - RC8

2. Currently available somatostatin analogs are not good for Graves’ orbitopathy

   • M. L. Tanda
   • L. Bartalena

   Editorial 11 March 2014 Pages: 389 - 390

3. Growth Hormone Registry: A step forward in standard diagnostic practices in Italy

   • M. Maghnie
   • N. di Iorgi

   Editorial 11 March 2014 Pages: 391 - 392

4. Dehydroepiandrosterone and human adipose tissue

   • F. Saraç
   • S. Yildiz
   • M. Tüzün

   Original Articles 11 March 2014 Pages: 393 - 398

5. Growth hormone replacement therapy in growth hormone deficient children and adults: Effects on hemochrome

   • S. Bergamaschi
   • C. Giavoli
   • P. Beck-Peccoz

   Original Articles 11 March 2014 Pages: 399 - 404

6. An empowerment-based educational program improves psychological well-being and health-related quality of life in Type 1 diabetes

   • G. Forlani
   • C. Zannoni
   • G. Marchesini

   Original Articles 11 March 2014 Pages: 405 - 412

7. Slow-release lanreotide in Graves’ ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial

   • T.-C. Chang
   • S.-L. Liao

   Original Articles 11 March 2014 Pages: 413 - 422

8. The newly developed three-dimensional (3D) and two-dimensional (2D) thyroid ultrasound are strongly correlated, but 2D overestimates thyroid volume in the presence of nodules

   • T. Rago
   • W. Bencivelli
   • P. Vitti

   Original Articles 11 March 2014 Pages: 423 - 426

9. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study

   • G. Papi
   • S. M. Corsello
   • E. Roti

   Original Articles 11 March 2014 Pages: 427 - 437

10. Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: Data from the GH Registry

    • G. Migliaretti
    • G. Aimaretti
    • F. Cavallo

    Original Articles 11 March 2014 Pages: 438 - 442

11. Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels

    • A. Benit
    • J. Allard
    • P. Caron

    Case Report 11 March 2014 Pages: 443 - 449

12. MEN1 family with a novel frameshift mutation

    • V. Nuzzo
    • L. Tauchmanová
    • A. Colao

    Case Report 11 March 2014 Pages: 450 - 456

13. An uncommon large deletion in the androgen-receptor gene in a XY female with complete androgen insensitivity syndrome

    • C. Moretti
    • T. Odorisio
    • P. Grimaldi

    Case Report 11 March 2014 Pages: 457 - 461

14. Pituitary size fluctuation in long-term MR studies of PROP1 deficient patients: A persistent pathophysiological mechanism?

    • A. Voutetakis
    • A. Sertedaki
    • M. I. Argyropoulou

    Case Report 11 March 2014 Pages: 462 - 466

15. Preventing skeletal complications in androgen deprived men with prostate cancer: Time for action

    • M. Braga-Basaria
    • S. Basaria

    Opinion 11 March 2014 Pages: 467 - 470

16. Endogenous subclinical hypercortisolism: Diagnostic uncertainties and clinical implications

    • S. Tsagarakis
    • D. Vassiliadi
    • N. Thalassinos

    Review Article 11 March 2014 Pages: 471 - 482

17. 12^th International Congress on Hormonal Steroids and Hormones & Cancer

    Announcement 11 March 2014 Pages: 483 - 483

18. European Thyroid Association

    Announcement 11 March 2014 Pages: 484 - 484